# Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model

> **NCT01527188** · PHASE2 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 355 (actual)

## Conditions studied

- Allergic Rhinitis Due to House Dust Mite

## Interventions

- **DRUG:** 100 IR house dust mites allergen extract tablet
- **DRUG:** 300 IR house dust mites allergen extract tablet
- **DRUG:** 500 IR house dust mites allergen extract tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT01527188
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-08
- **Primary completion:** 2012-03
- **Final completion:** 2012-09-19
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527188, "Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT01527188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*